Lipoprotein lipase during heparin infusion: lower activity in hemodialysis patients

REFERENCES

• Yukawa S, Mune M, Yamada Y, Otani H, Kishino M, Tone Y. Ongoing clinical trials of lipid reduction therapy in patients with renal disease Kidney Int Suppl 1999; 71: S141–3.
   Google Scholar
• Raine AE, Margreiter R, Brunner FP, Ehrich JH, Geerlings W, Landais P, Loirat C, Mallick NP, Selwood NH, Tufveson G, Valderrabano F. Report on management of renal failure in Europe, XXII, 1991 Nephrol Dial Transplant 1992; 7: 7–35.
   Google Scholar
• LaRosa JC, Hunninghake D, Bush D, Criqui MH, Getz GS, Gotto AM, Jr., Grundy SM, Rakita L, Robertson RM, Weisfeldt ML, Cleeman JI. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Associa-tion Circulation 1990; 81: 1721–33.
   Google Scholar
• Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men Am J Cardiol 1996; 77: 1179 — 84.
   Google Scholar
• Koch M, Kutkuhn B, Trenkwalder E, Bach D, Grabensee B, Dieplinger H, Kronenberg F. Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coron-ary artery disease in hemodialysis patients J Am Soc Nephrol 1997; 8: 1889–98.
   Google Scholar
• Bagdade JD, Porte D, Jr, Bierman EL. Hyper-triglyceridemia. A metabolic consequence of chronic renal failure N Engl J Med 1968; 279: 181–5.
   Google Scholar
• Arnadottir M, Nilsson-Ehle P. Parathyroid hor-mone is not an inhibitor of lipoprotein lipase activity Nephrol Dial Transplant 1994; 9: 1586–9.
   Google Scholar
• Shoji T, Nishizawa Y, Kawagishi T, Tanaka M, Kawasaki K, Tabata T, Inoue T, Morii H. Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis Atherosclerosis 1997; 131: 229–36.
   Google Scholar
• Samuelsson 0, Attman PO, Knight-Gibson C, Kron B, Larsson R, Mulec H, Weiss L, Alaupovic P. Lipoprotein abnormalities without hyperlipid-aemia in moderate renal insufficiency Nephrol Dial Transplant 1994; 9: 1580–5.
   Google Scholar
• Goldberg U. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis J Lipid Res 1996; 37: 693–707.
   Google Scholar
• Olivecrona T, Olivecrona G. Lipoprotein and hepatic lipases in lipoprotein metabolism In: Betteridge DJ, Illingworth DR, Shepard J, editors. Lipoproteins in health and disease. London: Arnold, 1999. p. 223–46.
   Google Scholar
• Mead JR, Cryer A, Ramji DP. Lipoprotein lipase, a key role in atherosclerosis? FEBS Lett 1999; 462: 1–6.
   PubMed Web of Science ®Google Scholar
• Olivecrona T, Olivecrona G. Determination and clinical significance of lipoprotein lipase and hepatic lipase In: Rifai N, Warnick G, Domin-iczak M, editors. Handbook of lipoprotein testing. Washington DC: AACC Press, 2000. p. 479–97.
   Google Scholar
• Bagdade JD. Uremic lipemia. An unrecognized abnormality in triglyceride production and removal Arch Intern Med 1991; 126: 875–81.
   Google Scholar
• Chan MK, Persaud J, Varghese Z, Moorhead JF. Pathogenic roles of post-heparin lipases in lipid abnormalities in hemodialysis patients Kidney Int 1984; 25: 812–8.
   Google Scholar
• Goldberg A, Sherrard DJ, Brunzell JD. Adipose tissue lipoprotein lipase in chronic hemodialysis: role in plasma triglyceride metabolism J Clin Endocrinol Metab 1978; 47: 1173–82.
   Google Scholar
• Roullet JB, Lacour B, Yvert JP, Prat JJ, Drueke T. Factors of increase in serum triglyceride-rich lipoproteins in uremic rats Kidney Int 1985; 27: 420–5.
   Google Scholar
• Vaziri ND, Liang K. Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure Kidney Int 1996; 50: 1928–35.
   Google Scholar
• Murase T, Cattran DC, Rubenstein B, Steiner G. Inhibition of lipoprotein lipase by uremic plasma, a possible cause of hypertriglyceridemia Metabolism 1975; 24: 1279–86.
   Google Scholar
• Cheung AK, Parker CJ, Ren K, Iverius PH. Increased lipase inhibition in uremia: identification of pre-beta-HDL as a major inhibitor in normal and uremic plasma Kidney Int 1996; 49: 1360–71.
   Google Scholar
• Arnadottir M, Dallongeville J, Fruchart JC, Nilsson-Ehle P. Very-low-density lipoprotein of uremic patients is a poor substrate for bovine lipoprotein lipase in vitro Metabolism 1996; 45: 686–90.
   Google Scholar
• Chevreuil 0, Hultin M, Ostergaard P, Olivecrona T. Depletion of lipoprotein lipase after heparin administration Arterioscler Thromb 1993; 13: 1391–6.
   Google Scholar
• Nestel PJ. The depletion and restoration of post-heparin lipolytic activity in the human forearm Proc Soc Exp Biol Med 1970; 134: 896–9.
   PubMed Web of Science ®Google Scholar
• Schrader J, Andersson LO, Armstrong VW, Kundt M, Stibbe W, Scheler F. Lipolytic effects of heparin and low molecular weight heparin and their importance in hemodialysis Semin Thromb Hemos 1990; 16 Suppl: 41–5.
   Google Scholar
• Weintraub M, Rassin T, Eisenberg S, Ringel Y, Grosskopf I, Iaina A, Charach G, Liron M, Rubinstein A. Continuous intravenous heparin administration in humans causes a decrease in serum lipolytic activity and accumulation of chylomicrons in circulation J Lipid Res 1994; 35: 229–38.
   Google Scholar
• Nasstrom B, Olivecrona G, Olivecrona T, Stegmayr BG. Lipoprotein lipase during contin-uous heparin infusion: tissue stores become partially depleted J Lab Clin Med 2001; 138: 206— 13.
   Google Scholar
• Majerus P, Broze GJ, Miletich J, Tollefsen D. Anticoagulant, thrombolytic, and antiplatelet drugs In: Hardman J, Limbird L, Molinoff P, Ruddon R, Goodman Gilman A, editors. Goodman & Gilman's the pharmacological basis of thera-peutics: 9th ed. London: McGraw-Hill, 1996. p. 14;1341–59.
   Google Scholar
• Koerber JM, Smythe MA, Begle RL, Mattson JC, Kershaw BP, Westley SJ. Correlation of activated clotting time and activated partial thrombo-plastin time to plasma heparin concentration Pharmacotherapy 1999; 19: 922–31.
   Google Scholar
• Vilaro S, Llobera M, Bengtsson-Olivecrona G, Olivecrona T. Lipoprotein lipase uptake by the liver: localization, turnover, and metabolic role Am J Physiol 1988; 254: G711 — 22.
   Google Scholar
• Thompson PD, Kantor MA, Cullinane EM, Sady SP, Saritelli A, Herbert PN. Postheparin plasma lipolytic activities in physically active and sedentary men after varying and repeated doses of intravenous heparin Metabolism 1986; 35: 999 — 1004.
   Google Scholar
• Hahn P. Abolishment of alimentary lipemia following injection of heparin Science 1943; 98: 19 — 20.
   Google Scholar
• Alsayed N, Rebourcet R. Abnormal concentra-tions of CII, CIII, and E apolipoproteins among apolipoprotein B-containing, B-free, and A-I-containing lipoprotein particles in hemodialysis patients Clin Chem 1991; 37: 387 — 93.
   Google Scholar